Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Recher

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
Blood Cancer Journal|March 29, 2025
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemiaVinod Pullarkat, Keith W Pratz, Hartmut Döhner, et al.
Blood|August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialThorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Cancer Medicine|August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysisStéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Blood|July 19, 2015
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionNathalie Jacque, Anne Marie Ronchetti, Clément Larrue, et al.
Blood|April 7, 2006
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cellsMarion Gabillot-Carré, Yves Lepelletier, Martine Humbert, et al.
American Journal of Hematology|January 22, 2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patientsBruno Royer, Lavinia Merlusca, Julie Abraham, et al.
Blood|September 17, 2015
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA studyChristiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
Blood Cancer Journal|March 29, 2025
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemiaVinod Pullarkat, Keith W Pratz, Hartmut Döhner, et al.
Blood|August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialThorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Cancer Medicine|August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysisStéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Blood|July 19, 2015
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionNathalie Jacque, Anne Marie Ronchetti, Clément Larrue, et al.
Blood|April 7, 2006
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cellsMarion Gabillot-Carré, Yves Lepelletier, Martine Humbert, et al.
American Journal of Hematology|January 22, 2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patientsBruno Royer, Lavinia Merlusca, Julie Abraham, et al.
Blood|September 17, 2015
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA studyChristiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Pageof 14